Phathom Pharmaceuticals, a Phase 3 biotech developing novel therapies for gastrointestinal diseases, raised $182 million by offering 9.6 million shares at $19, the midpoint of the $18 to $20 range. The company upsized its offering by 21%. Phathom Pharmaceuticals plans to list on the Nasdaq under the symbol PHAT. Goldman Sachs, Jefferies and Evercore ISI acted as lead managers on the deal.
